Cap +1 mutation; an unsuspected cause of beta thalassaemia transmission in Pakistan by Sadia Usman Babar et al.
167 Research Article  
Cap +1 mutation; an unsuspected cause of beta 
thalassaemia transmission in Pakistan
Cap +1 mutasyon; Pakistan’da beta talasemi taşıyıcılığının şüphe götürmez bir 
nedeni
Muhammad Usman Abdul Karim, Moinuddin Moinuddin, Sadia Usman Babar
Institute of Hematology Baqai Medical University, Karachi, Pakistan
Address for Correspondence: Asst. Prof. Muhammad Usman Abdul Karim, Super High Way Near Toll Plaza Karachi, Pakistan Karachi, Pakistan
Phone: +92-322-3561923   E-mail: staytune1@hotmail.com
Abstract
Objective: Thalassemia is one of the most common genetic disorders worldwide. Cap +1 mutation which causes ‘silent 
beta thalassemia’ is present around all ethnic groups of Pakistan. This study was designed to detect the frequency of 
Cap+1 mutation in Pakistani Population.
Materials and Methods: Molecular genetic for Cap+1 beta thalassemic mutation was done by extracting DNA from whole 
blood by using Genomic DNA Purification Kit (Gentra system USA). Amplification Refractory Mutation System (ARMS) 
primers were designed for detection of normal and mutant DNA.
Basic hematological parameters were performed by using automated analyzer (Sysmex KX-21). Cellulose acetate hemo-
globin electrophoresis was done by using semi-automated technique (INTERLAB Roma Microtech Series Electrophoresis 
system 4.23). 
Results: The frequency of Cap+1 mutation was observed 5% (10/200) in targeted thalassemic families (having patients 
with beta-thalassemia intermedia) while its frequency was observed 2% (12/600) in total thalassemic genes in Pakistani 
population. 
Conclusion: Cap+1 (A-C) is a silent mutation and it has very minimum effect on beta globin synthesis because of which 
it produces very less clinical severity and certain important laboratory diagnostic tests like basic hematological parameters 
and Hb A2 levels are also remain in normal range. Therefore individuals with Cap+1 mutation may produce children with 
beta-thalassemia intermedia if they marry an individual with beta-thalassemia minor. Cap+1 (A-C) mutation is an unsus-
pected cause of beta thalassemia transmission in Pakistani population. This mutation can identify at molecular level. As 
this molecular defect is difficult to diagnose in Laboratory with routine laboratory tests because of that it has become a 
serious hindrance for thalassemia prevention program in Pakistan. (Turk J Hematol 2009; 26: 167-70)
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Özet
Amaç: Talasemi dünya genelinde en yaygın genetik bozukluklardan biridir. ‘Sessiz beta talasemi’ye neden olan Cap +1 
mutasyonu Pakistan’daki tüm etnik gruplarda görülmektedir. Bu çalışma Pakistan nüfusu içinde Cap +1 mutasyonun 
sıklığını belirlemek için tasarlanmıştır.Introduction
Thalassemia is the most common genetic disorder across 
the globe [1,2]. The term thalassemia comes from a Greek 
word “thalas” which means the sea, and “emia” that stands for 
blood [3,4]. The composite word came into use because this 
type of anemia was originally described only in countries 
bordering the Mediterranean Sea. Thalassemia was not 
recognized as a clinical entity until 1925, when Cooley and 
Lee, described a syndrome occurring early in life that was 
associated with splenomegaly and bony deformities [4]. 
Beta thalassemia is the most common genetic disorder in 
Pakistan [5]. Pakistan has a population of 160 million people 
[6]. The annual rate of population growth is 3% and almost 
40% of the population is below 15 years of age [7,8]. There are 
five major ethnic groups Punjabi, Pathan, Sindhi, Baluchi and 
Urdu speaking. Each ethnic group is subdivided into Casts or 
‘Biradris’ of people ranging from a few thousands to a few 
millions. There is a very strong tradition for people to marry 
within their Biradris. Among very common custom is marriage 
between close relatives, especially the first cousins [8]. 
A number of studies have been done worldwide at 
molecular level to describe mutations, deletions and 
substitutions in beta globin gene causing beta thalassemia with 
different clinical severity. More than 200 causative molecular 
defects have so far been described in the ß-globin gene 
causing beta thalassemia [9]. Thirteen mutations are commonly 
reported in Pakistani population in which five are the most 
common mutations; these include IVS-1-5 (G-C), Frameshift 
(Fs) 8/9 (+G), Fs 41/42 (-TTCT), IVS-1-1 (G-T) and Del 619. 
Other mutations that were reported in Pakistani population are 
a few uncommon and some rare mutations [8,10]. Cap +1 
(A-C) mutation is a silent mutation causes ‘silent beta 
thalassemia’ [10,11]. This mutation is present in all ethnic 
groups of Pakistan. 
This study was designed to detect the prevalence of Cap+1 
(A-C) mutation in Pakistan, to determine its effect on basic 
hematological parameters and Hb-A2 levels and to reveal the 
role of this mutation in propagation of beta thalassemia gene in 
Pakistani population.
Material and Methods
This molecular study was performed at Baqai Institute of 
hematology, Baqai Medical University, Karachi from March 
2004 to April 2009. Venous blood samples from 610 patients 
with beta thalassemia major, beta thalassemia intermedia and 
beta thalassemia minor were collected in EDTA. Test population 
was divided into two groups; one group comprised of targeted 
families (having children with thalassemia intermedia) while the 
second group included random samples from patients with 
beta thalassemia major and minor.
All samples were tested by the modified method of 
Amplification of Refractory Mutation System (ARMS) for Cap+1 
(A-C) mutation. Basic hematological parameters and Hb-A2 
levels were also done on blood samples that had Cap+1 
mutation. 
Basic hematological parameters were determined by 
automated analyzer (Sysmex KX-21). Cellulose acetate 
hemoglobin electrophoresis was done by semi-automated 
technique (INTERLAB Roma Microtech Series Electrophoresis 
system 4.23). 
DNA was extracted from whole blood by using Genomic 
DNA Purification Kit (Gentra system USA). Amplification 
refractory mutation system (ARMS) primers were designed for 
detection of normal and mutant DNA. A control pair of primers 
was included in each assay. Control primers A, B and C were 
amplified at 861 bp fragments from 3’ end of the ß globin gene 
[12,13]. 
PCR was conducted with modified method in a mixture of 
10 mmol/l tris (pH 8.3), 50 mmol/l KCl, 1.5 mmol/l MgCl2. 500 
μM each dNTP’s, 0.2 μmol/l of each primer, 0.5 units of 
Thermus aqaticus (Taq) 0.5 to 1 pg of genomic DNA was 
added to the PCR mixture in a total volume of 20 μl. The 
modified cycling reaction (DNA thermal cycle; Perkin-Elmer/
Cetus) was programmed at 94
oC for 1 minute (denature), 65
oC 
for 1 minute (anneal) and 72
oC for 1.5 minutes (extend). After 
25 cycles, the samples were incubated for an additional 3 
minutes at 66
oC [12,13]. 
The amplified PCR products were observed using agarose 
gel electrophoresis and mutation was characterized with 100 
bp or 50 bp ladder. 
Yöntem ve Gereçler: Cap +1 beta talasemik mutasyon tayini Genomik DNA Purifikasyon Kiti (Gentra system ABD) 
kullanılarak kandan ekstre edildi. Normal ve mutant DNA tespiti için Amplifikasyon Refrakter Mutasyon Sistemi (ARMS) 
primerleri tasarlandı.Temel hematolojik parametreler otomatik analizör (Sysmex KX-21) kullanılarak çalışıldı. Selüloz asetat 
hemoglobin elektroforezi yarı-otomatik teknik (INTERLAB Roma Microtech Series Electrophoresis system 4.23) kullanılarak 
yapıldı. 
Bulgular:  Cap+1 mutasyon sıklığı, hedef talasemik ailelerde (beta-talasemi intermedia hastaları) %5 (10/200) olarak 
gözlemlenirken bu sıklık Pakistan popülasyonu içindeki total talasemik genlerde %2 (12/600) olarak bulundu.
Sonuç: Cap+1 (A-C) sessiz bir mutasyondur ve beta globin sentezi üzerinde minimum bir etkiye sahiptir. Bu yüzden klinik 
önemi azdır. Hematolojik parametreler ve Hb A2 seviyeleri gibi önemli laboratuvar tanı testleri de normal düzeyde 
kalmaktadır. Bu nedenle Cap+1 mutasyonu taşıyan bireyler eğer beta-talasemi minör bulunan bir bireyle evlenirlerse beta-
talasemi intermediyalı çocuğa sahip olabilir. Pakistan popülasyonunda Cap+1 (A-C) mutasyon taşıyıcılığı, beta talasemi 
taşınmasının nadir ve şüphe duyulmayan bir nedenidir. Bu mutasyon moleküler düzeyde belirlenebilir. Bu moleküler bozuk-
luk Polimeraz Zincir Reaksiyon (PCR) yardımı olmadan laboratuvarda zor teşhis edilebileceği için Pakistan’daki talasemi 
önleme programı için ciddi bir engel haline gelmiştir. (Turk J Hematol 2009; 26: 167-70) 
Anahtar kelimeler: Cap+1(A-C) mutasyon, sessiz beta talasemi, polimeraz zincir reaksiyonu (PCR)
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Results were analyzed using SPSS statistical software 
version 13.
Results
Result of the first group which included 160 individuals from 
targeted families (having children with thalassemia intermedia) 
identified 200 beta thalassemia genes in which frequency of 
Cap+1(A-C) mutation was observed at 5% (10/200). While 
result of the second group which included 450 random 
samples from patients with beta thalassemia major and minor 
revealed 600 beta thalassemia genes in which frequency of 
Cap+1(A-C) mutation was 2% (12/600) in Pakistani population. 
Prevalence of this mutation in five major ethnic groups was 
observed with a frequency of 2.1% in Punjabi’s, 1.7% in 
Pathan’s, 1.7% in Sindhis, 2% in Baluchi’s and 2.5% in Urdu 
speaking population of Pakistan.
Discussion
Result of this study revealed that Cap+1(A-C) is one of the 
common mutation which is present in all major ethnic groups 
of Pakistan. Frequency of Cap+1 (A-C) mutation was observed 
at 5% (10/200) in targeted beta thalassemic families (having 
patients with beta thalassemia intermedia) while its frequency 
was 2% (12/600) in total beta thalassemic genes in Pakistani 
population. Prevalence of this mutation in five major ethnic 
groups was observed with a frequency of 2.1% in Punjabi’s, 
1.7% in Pathan’s, 1.7% in Sindhis, 2% in Baluchi’s and 2.5% 
in Urdu speaking population of Pakistan.
Cap+1(A-C) mutation is also reported in Indian population 
and U.A.E (United Arab Emirates) nationals [14-18]. This 
mutation is also identified in Arab population (Jordan, Egypt, 
Syria, Lebanon, Yemen and Saudi Arabia) [19]. Cap+1 mutation 
is also reported in Malaysian population [20]. 
This study revealed that Cap+1 (A-C) is a silent mutation 
and it has only minimal effect on beta globin synthesis. 
Because of this it produces very few clinical manifestations. 
Also various basic hematological parameters (Hb, RBC, MCV, 
MCH, MCHC) and Hb A2 levels remain in normal range (Table 
1). Commonly prevalent beta thalassemia mutations other than 
Cap+1(A-C) mutation present in Pakistani population show 
characteristic hematological variation in the form of low Hb, 
increased RBC count, decreased MCV, decreased MCH, 
normal MCHC and increased level of Hb-A2. Because of the 
negligible effect of Cap+1 mutation on these hematological 
parameters and Hb-A2 levels it is difficult to diagnose beta 
thalassemia minor caused by Cap+1(A-C) mutation. Molecular 
techniques like PCR are essential for the diagnosis of beta 
thalassemia minor associated with Cap+1 mutation. 
It is therefore important to accurately diagnose Cap+1 
mutation lest it propagates beta thalassemia major as a result 
of marriage between a known case of beta thalassemia minor 
and a “normal” individual for beta thalassemia minor who 
indeed is a carrier of Cap+1 mutation which remain undetected 
on routine hematological parameters including 
Hb-electrophoresis for Hb-A2 level. 
This mutation was not observed in homozygous state 
during this study and no case of beta thalassemia major was 
identified having Cap+1 (A-C) mutation. This mutation was 
observed as one of the most important molecular defects 
causing beta thalassemia intermedia if inherited with other 
major beta thalassemic genes reported in Pakistani population. 
Therefore individuals with Cap+1 mutation may produce 
children with beta thalassemia intermedia if they marry an 
individual with beta-thalassemia minor. Cap+1 (A-C) mutation 
is an uncommon and unsuspected cause of beta thalassemia 
transmission in Pakistani population. Population study at a 
larger scale should be conducted to determine the frequency 
of CAP+1 mutation in Pakistani population; this will stop the 
propagation of thalassemia genes in homozygous state and 
prevent the birth of children with beta thalassemia intermedia.
No author of this paper has a conflict of interest, including 
specific financial interests, relationships, and/or affiliations 
relevant to the subject matter or materials included in this 
manuscript.
Table 1. Basic hematological parameters and Hb-A2 levels of beta thalassemia minor with Cap+1 mutation
Group No.  of  Hb  RBC  MCV MCH  MCHC  Hb-A2 
 samples  (gm/dl)  (millions/ul)  (fl)  (pg)  (gm  %)  (%)
Male  12  13.6 (±0.37)  4.8 (±0.34)  84.8 (±5.2)  29 (±1.37)  32.7 (±1.4)  3.0 (±0.12)
Female 10 
Total no. of samples  22
    12.0 (±0.71)  4.0 (±0.7)  80.4 (±3.1)  28.4 (±0.78)  31.4 (±1.8)  3 (±0.19)
Control 861 bp
Cap+1 567 bp
Control 861 bp
Cap+1 567 bp
Figure 1. Analysis of DNA sample with mutation primers Cap+1 (A-C) using 100 
bp ladder
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